VivoSeq
Other

AMD

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

AMD is an early-stage landscape with 0 programs across 2 companies. The most active players are Progen Pharmaceuticals, Regeneron.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

90/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Progen Pharmaceuticals

0 programs

PreclinicalRegeneron logo

Regeneron

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed9 · 90%
Withdrawn1 · 10%

Clinical Trials

Trial Activity

10 trials

Anecortave Acetate Versus Placebo in AMD Patients Following PDT
Completed·AAlcon Research·Phase 2·NCT00346866·136 enrolled
Ranibizumab and Reduced Fluence PDT for AMD
Completed·TTexas Retina Associates·Phase 2·NCT00527475·60 enrolled
Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD
Completed·PProgen Pharmaceuticals·Phase 1·NCT00446654·43 enrolled
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
Completed·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT00413829·20 enrolled
Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD
Completed·MMaturi, Raj K., M.D., P.C.·Phase 2·NCT02732899·20 enrolled
Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD
Completed·Regeneron logoRegeneron·Phase 1·NCT00383370·20 enrolled
Single or Combined Protocols for NV-AMD
Completed·UUniversity Hospital of Ferrara·Phase 4·NCT03552770·109 enrolled
Scotoma Reduction in AMD Patients Treated With Ranibizumab
Completed·RRetina Research Foundation·Phase 1/2·NCT00467935·20 enrolled
ERG/EOG Study in AMD Patients Treated With Ranibizumab
Completed·RRetina Center, Minnesota·N/A·NCT00791427·10 enrolled
Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD
Withdrawn·—·N/A·NCT02457026

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)